论文部分内容阅读
目的观察替比夫定治疗慢性乙型肝炎(CHB)患者抗病毒的疗效。方法将102例入选的慢性乙型肝炎(CHB)患者随机分成治疗组和对照组,治疗组52例用替比夫定600mg,每日一次,口服,患者基本疗程12个月,6个月无治疗应答者停药。对照组50例用普通干扰素IFN-α500u,隔日一次,肌肉注射,患者基本疗程12个月,6个月无治疗应答者停药。不同时给予常规保肝治疗。观察治疗期间,患者血清ALT复常率,HBV-DNA阴转率,HBeAg、HBeAb转换率,以及不良反应。结果治疗组血清ALT复常率,HBV-DNA阴转率,HBeAg、HBeAb转换率均高于对照组,分别为90.4%(47/52)、70.0%(35/50)(P<0.05);67.3%(35/52)、36.0%(18/50)(P<0.05);57.7%(30/52),26.0%(13/50)(P<0.05);替比夫定无明显不良反应,干扰素不良反应较多。结论替比夫定治疗慢性乙型肝炎(CHB)较干扰素更能够取得良好的抗病毒效果,更易被患者接受。
Objective To observe the efficacy of telbivudine in the treatment of patients with chronic hepatitis B (CHB) antiviral therapy. Methods A total of 102 patients with chronic hepatitis B (CHB) were randomly divided into treatment group and control group. In the treatment group, 52 patients were treated with telbivudine 600 mg orally once daily for 12 months and 6 months Treatment responders were discontinued. The control group of 50 patients with ordinary interferon IFN-α500u, every other day, intramuscular injection, the patient basic course of 12 months, 6 months no treatment response were discontinued. Do not give regular liver protection at the same time. During treatment, patients with ALT normalization rate, HBV-DNA negative conversion rate, HBeAg, HBeAb conversion rate, and adverse reactions. Results The ALT normalization rate, HBV - DNA negative conversion rate, HBeAg and HBeAb conversion rates in the treatment group were significantly higher than those in the control group (90.4%, 70/50, respectively) (P <0.05). 67.3% (35/52), 36.0% (18/50) (P <0.05); 57.7% (30/52), 26.0% (13/50) , Interferon more adverse reactions. Conclusion Telbivudine treatment of chronic hepatitis B (CHB) than interferon better able to get a good antiviral effect, more easily accepted by patients.